Skip to main content
ArticleOPEN ACCESS

Response to: The BRAIN TRIAL: A randomized, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury - authors' reply

Trials
DOI: 10.1186/1745-6215-10-111
0Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

A response to the letter regarding The BRAIN TRIAL: a randomized, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury, by Mr Vincent Simmon President and CEO of Xytis Inc. © 2009 Roberts and Shakur; licensee BioMed Central Ltd.

Cite

CITATION STYLE

APA

Roberts, I., & Shakur, H. (2009, December 3). Response to: The BRAIN TRIAL: A randomized, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury - authors’ reply. Trials. https://doi.org/10.1186/1745-6215-10-111

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free